Insmed Statistics
Total Valuation
Insmed has a market cap or net worth of $30.17 billion. The enterprise value is $29.84 billion.
Important Dates
The next estimated earnings date is Thursday, May 7, 2026, before market open.
| Earnings Date | May 7, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Insmed has 215.55 million shares outstanding. The number of shares has increased by 21.32% in one year.
| Current Share Class | 215.55M |
| Shares Outstanding | 215.55M |
| Shares Change (YoY) | +21.32% |
| Shares Change (QoQ) | +0.89% |
| Owned by Insiders (%) | 0.64% |
| Owned by Institutions (%) | 90.32% |
| Float | 193.14M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 50.32 |
| Forward PS | 21.87 |
| PB Ratio | 41.75 |
| P/TBV Ratio | 57.77 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 49.20 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 3.83, with a Debt / Equity ratio of 1.01.
| Current Ratio | 3.83 |
| Quick Ratio | 3.35 |
| Debt / Equity | 1.01 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -11.87 |
Financial Efficiency
Return on equity (ROE) is -249.28% and return on invested capital (ROIC) is -40.32%.
| Return on Equity (ROE) | -249.28% |
| Return on Assets (ROA) | -28.99% |
| Return on Invested Capital (ROIC) | -40.32% |
| Return on Capital Employed (ROCE) | -55.40% |
| Weighted Average Cost of Capital (WACC) | 10.63% |
| Revenue Per Employee | $364,437 |
| Profits Per Employee | -$767,293 |
| Employee Count | 1,664 |
| Asset Turnover | 0.28 |
| Inventory Turnover | 1.07 |
Taxes
In the past 12 months, Insmed has paid $5.03 million in taxes.
| Income Tax | 5.03M |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +78.17% in the last 52 weeks. The beta is 1.17, so Insmed's price volatility has been higher than the market average.
| Beta (5Y) | 1.17 |
| 52-Week Price Change | +78.17% |
| 50-Day Moving Average | 152.77 |
| 200-Day Moving Average | 147.79 |
| Relative Strength Index (RSI) | 40.12 |
| Average Volume (20 Days) | 1,964,001 |
Short Selling Information
The latest short interest is 11.28 million, so 5.23% of the outstanding shares have been sold short.
| Short Interest | 11.28M |
| Short Previous Month | 11.49M |
| Short % of Shares Out | 5.23% |
| Short % of Float | 5.84% |
| Short Ratio (days to cover) | 4.70 |
Income Statement
In the last 12 months, Insmed had revenue of $606.42 million and -$1.28 billion in losses. Loss per share was -$6.42.
| Revenue | 606.42M |
| Gross Profit | 483.49M |
| Operating Income | -994.78M |
| Pretax Income | -1.27B |
| Net Income | -1.28B |
| EBITDA | -980.46M |
| EBIT | -994.78M |
| Loss Per Share | -$6.42 |
Full Income StatementBalance Sheet
The company has $1.43 billion in cash and $749.54 million in debt, with a net cash position of $680.51 million or $3.16 per share.
| Cash & Cash Equivalents | 1.43B |
| Total Debt | 749.54M |
| Net Cash | 680.51M |
| Net Cash Per Share | $3.16 |
| Equity (Book Value) | 738.98M |
| Book Value Per Share | 3.45 |
| Working Capital | 1.33B |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$935.01 million and capital expenditures -$32.56 million, giving a free cash flow of -$967.58 million.
| Operating Cash Flow | -935.01M |
| Capital Expenditures | -32.56M |
| Depreciation & Amortization | 14.31M |
| Net Borrowing | -4.93M |
| Free Cash Flow | -967.58M |
| FCF Per Share | -$4.49 |
Full Cash Flow StatementMargins
Gross margin is 79.73%, with operating and profit margins of -164.04% and -210.54%.
| Gross Margin | 79.73% |
| Operating Margin | -164.04% |
| Pretax Margin | -209.71% |
| Profit Margin | -210.54% |
| EBITDA Margin | -161.68% |
| EBIT Margin | -164.04% |
| FCF Margin | n/a |
Dividends & Yields
Insmed does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -21.32% |
| Shareholder Yield | -21.32% |
| Earnings Yield | -4.18% |
| FCF Yield | -3.17% |
Dividend DetailsAnalyst Forecast
The average price target for Insmed is $190.43, which is 36.05% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $190.43 |
| Price Target Difference | 36.05% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 24 |
| Revenue Growth Forecast (5Y) | 61.23% |
| EPS Growth Forecast (5Y) | n/a |
Stock ForecastsFair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
The last stock split was on March 3, 2011. It was a reverse split with a ratio of 1:10.
| Last Split Date | Mar 3, 2011 |
| Split Type | Reverse |
| Split Ratio | 1:10 |
Scores
Insmed has an Altman Z-Score of 5.13 and a Piotroski F-Score of 4.
| Altman Z-Score | 5.13 |
| Piotroski F-Score | 4 |
